Company Description
BiomX Inc., a clinical-stage biopharmaceutical company, develops phage-based therapies using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases.
The company’s phage-based therapies include fixed cocktail therapy, which involves developing a single product containing a fixed number of selected phages to cover a range of bacterial strains; and personalized therapy, which involves developing a large library of phages from which single optimal phages are personally matched to treat specific patients.
It develops BX011, a fixed multi-phage cocktail, which is in Phase 2a trial for the treatment of diabetic foot infections; and BX211, a phage therapy, which is in Phase 2 trial for the treatment of diabetic foot osteomyelitis.
BiomX Inc. was founded in 2015 and is based in Dover, Delaware.
| Country | United States |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 20 |
| CEO | Michael Oster |
Contact Details
Address: 850 New Burton Road, Suite 201 Dover, Delaware 19904 United States | |
| Website | biomx.com |
Stock Details
| Ticker Symbol | PHGE |
| Exchange | NYSEAMERICAN |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1739174 |
| CUSIP Number | 09090D103 |
| ISIN Number | US09090D5095 |
| Employer ID | 82-3364020 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Michael Oster | Chief Executive Officer |
| Marina Wolfson CPA | Secretary |
| Prof. Rotem Sorek Ph.D. | Scientific Founder |
| Dr. Eran Elinav M.D., Ph.D. | Scientific Founder |
| Dr. Timothy K. Lu M.D., Ph.D. | Scientific Founder |
| Dr. Carl R. Merril M.D. | Scientific Founder |
| David Rokach | Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer |
| Inbal Benjamini-Elran | C.H.R.O |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 27, 2026 | 8-K | Current Report |
| Mar 25, 2026 | DEF 14A | Other definitive proxy statements |
| Mar 19, 2026 | 8-K | Current Report |
| Mar 11, 2026 | 8-K | Current Report |
| Mar 6, 2026 | 8-K | Current Report |
| Mar 2, 2026 | 8-K | Current Report |
| Feb 25, 2026 | 8-K | Current Report |
| Feb 19, 2026 | 10-K | Annual Report |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 13, 2026 | EFFECT | Notice of Effectiveness |